Read by QxMD icon Read

Pauline Funchain

Tarek Ashour, Georges Nakhoul, Pradnya Patil, Pauline Funchain, Leal Herlitz
No abstract text is available yet for this article.
February 2019: KI Reports
Pradnya D Patil, Anthony P Fernandez, Vamsidhar Velcheti, Ahmad Tarhini, Pauline Funchain, Brian Rini, Mohamad Khasawneh, Nathan A Pennell
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment paradigms for a broad spectrum of malignancies. Because immune checkpoint inhibitors rely on immune reactivation to eliminate cancer cells, they can also lead to the loss of immune tolerance and result in a wide range of phenomena called immune-related adverse events (irAEs). At our institution, the management of irAEs is based on multidisciplinary input obtained at an irAE tumor board that facilitates expedited opinions from various specialties and allows for a more uniform approach to these patients...
October 24, 2018: Oncologist
Jennifer S Ko, Brian R Gastman, Ruzica Conic, Alejandra Tellez Diaz Trujillo, Claudia Marcela Diaz-Montero, Steven D Billings, Ahmad Tarhini, Pauline Funchain, Natasha Atanaskova Mesinkovska
INTRODUCTION: Pregnancy depends on tolerance of an immunologically foreign fetus through type 1 T-cell suppression. Worse melanoma outcomes have been described within 1 year of childbirth. We assessed immunopathologic factors that may account for the observed negative impact of pregnancy on outcome. MATERIALS AND METHODS: Women of child-bearing age with ≥24 months follow-up were identified from our Institutional Melanoma Registry. Women with available primary tumor blocks were compared [history of childbirth within 1 year of diagnosis (CB1Y) (n = 18) vs...
October 9, 2018: American Journal of Dermatopathology
Joanne M Jeter, Tawnya L Bowles, Clara Curiel-Lewandrowski, Susan M Swetter, Fabian V Filipp, Zalfa A Abdel-Malek, Larisa J Geskin, Jerry D Brewer, Jack L Arbiser, Jeffrey E Gershenwald, Emily Y Chu, John M Kirkwood, Neil F Box, Pauline Funchain, David E Fisher, Kari L Kendra, Ashfaq A Marghoob, Suephy C Chen, Michael E Ming, Mark R Albertini, John T Vetto, Kim A Margolin, Sherry L Pagoto, Jennifer L Hay, Douglas Grossman, Darrel L Ellis, Mohammed Kashani-Sabet, Aaron R Mangold, Svetomir N Markovic, Kelly C Nelson, Jennifer G Powers, June K Robinson, Debjani Sahni, Aleksandar Sekulic, Vernon K Sondak, Maria L Wei, Jonathan S Zager, Robert P Dellavalle, John A Thompson, Martin A Weinstock, Sancy A Leachman, Pamela B Cassidy
Recent progress in the treatment of advanced melanoma has led to unprecedented improvements in overall survival and, as these new melanoma treatments have been developed and deployed in the clinic, much has been learned about the natural history of the disease. Now is the time to apply that knowledge toward the design and clinical evaluation of new chemoprevention agents. Melanoma chemoprevention has the potential to reduce dramatically both the morbidity and the high costs associated with treating patients who have metastatic disease...
October 3, 2018: Cancer
Rosalynn R Z Conic, Jennifer Ko, Giovanni Damiani, Pauline Funchain, Thomas Knackstedt, Alok Vij, Allison Vidimos, Brian R Gastman
BACKGROUND: Sentinel lymph node biopsy (SLNB) specimens are often obtained from patients for further staging after these patients have undergone melanoma excision. Limited data regarding predictors of SLNB positivity in thin melanoma are available. OBJECTIVE: We sought to evaluate predictors of SLNB positivity in thin melanoma. METHODS: Patients with cutaneous melanoma with a Breslow thickness ≤1.00 mm who received a SLNB were identified from the National Cancer Database between 2004 and 2014 (n = 9186)...
September 18, 2018: Journal of the American Academy of Dermatology
Freeha Khan, Pauline Funchain, Ana Bennett, Tracy L Hull, Bo Shen
No abstract text is available yet for this article.
September 2018: Cleveland Clinic Journal of Medicine
Douglas B Johnson, Jennifer Bordeaux, Ju Young Kim, Christine Vaupel, David L Rimm, Thai H Ho, Richard W Joseph, Adil I Daud, Robert M Conry, Elizabeth M Gaughan, Leonel F Hernandez-Aya, Anastasios Dimou, Pauline Funchain, James Smithy, John S Witte, Svetlana B McKee, Jennifer Ko, John M Wrangle, Bashar Dabbas, Shabnam Tangri, Jelveh Lameh, Jeffrey Hall, Joseph Markowitz, Justin M Balko, Naveen Dakappagari
Purpose: PD-1/L1 axis-directed therapies produce clinical responses in a subset of patients; therefore, biomarkers of response are needed. We hypothesized that quantifying key immunosuppression mechanisms within the tumor microenvironment by multiparameter algorithms would identify strong predictors of anti-PD-1 response. Experimental Design: Pretreatment tumor biopsies from 166 patients treated with anti-PD-1 across 10 academic cancer centers were fluorescently stained with multiple markers in discovery ( n = 24) and validation ( n = 142) cohorts...
November 1, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Lillian Sun, Pauline Funchain, Jung Min Song, Patricia Rayman, Charles Tannenbaum, Jennifer Ko, Michael Mcnamara, C Marcela Diaz-Montero, Brian Gastman
BACKGROUND: Talimogene Laherparepvec (T-VEC) is an oncolytic virus approved as an intratumoral therapy for treating unresectable stage IIIB-IV metastatic melanoma. The mechanisms of action for T-VEC and checkpoint inhibitor are highly complementary. Recent studies have shown that combining checkpoint inhibitor therapy with T-VEC injection can lead to improved response rates for stage IIIB-IV melanoma patients. METHODS: We reviewed 10 consecutive cases of stage IIIC to stage IVM1b melanoma patients that received T-VEC plus checkpoint inhibitor(s) therapy (pembrolizumab, ipilimumab/nivolumab, or nivolumab) treated between June 2016 and August 2017 at the Cleveland Clinic with a median follow-up of 7 months (range: 4 to 13 months)...
May 16, 2018: Journal for Immunotherapy of Cancer
Pauline Funchain, Ahmad A Tarhini
Rapidly advancing genomic sequencing technologies are changing all areas of cancer, from diagnosis to surveillance, and prognostication to treatment. The role of genomic testing in melanoma is expanding, and multiple genomically based tests are available, including somatic tumor sequencing for actionable genetic alterations and tumor mutational burden, prognostic gene expression profiling from tumor tissue, and germline genetic testing from blood. The available testing options have varying levels of supporting data, from robust to preliminary...
March 15, 2018: Oncology (Williston Park, NY)
Joshua Arbesman, Sairekha Ravichandran, Pauline Funchain, Cheryl L Thompson
Identifying novel melanoma genetic risk factors informs screening and prevention efforts. Mutations in the phenylalanine hydroxylase gene (the causative gene in phenylketonuria) lead to reduced pigmentation in untreated phenylketonuria patients, and reduced pigmentation is associated with greater melanoma risk. Therefore, we sought to characterize the relationship between phenylketonuria carrier status and melanoma risk. Using National Newborn Screening Reports, we determined the United States phenylketonuria/hyperphenylalanemia carrier frequency in Caucasians to be 1...
July 2018: Pigment Cell & Melanoma Research
Evan Stiegel, David Xiong, Jason Ya, Pauline Funchain, Raymond Isakov, Brian Gastman, Alok Vij
BACKGROUND: Sentinel lymph node (SLN) biopsy is widely performed for melanoma with certain histologic parameters and offers important prognostic and staging information. Breslow thickness (BT) by itself also provides meaningful prognostic information. OBJECTIVE: To evaluate whether SLN status provides prognostic information independent from that which is already provided by BT. METHODS: We conducted a retrospective cohort study of 896 patients who underwent SLN biopsy for primary cutaneous melanoma...
May 2018: Journal of the American Academy of Dermatology
Vyshak Alva Venur, Pauline Funchain, Rupesh Kotecha, Samuel T Chao, Manmeet S Ahluwalia
Until recently, therapeutic strategies for melanoma brain metastases focused on local treatments: surgery, whole-brain radiation therapy, and stereotactic radiosurgery. Historically, systemic therapy had limited utility. Immunotherapeutic drugs, such as anti-cytotoxic T-lymphocyte-associated antigen 4 and anti-programmed death 1 agents, and agents targeting the BRAF-MEK pathway have revolutionized the systemic treatment of melanoma brain metastases. Recent clinical trials of these agents have shown activity against melanoma brain metastases, and they are increasingly being used in clinical practice...
September 15, 2017: Oncology (Williston Park, NY)
Vyshak Alva Venur, Pauline Funchain, Rupesh Kotecha, Samuel T Chao, Manmeet S Ahluwalia
Melanoma is the third most common cause of brain metastases, after lung and breast cancer. The management of melanoma brain metastases can be broadly divided into symptom control and therapeutic strategies. Supportive treatments include corticosteroids to reduce peritumoral edema, antiepileptics for seizure control, and medications to preserve cognitive function. Until recently, therapeutic strategies consisted primarily of local treatments, including surgery, whole-brain radiation therapy (WBRT), and stereotactic radiosurgery (SRS)...
August 15, 2017: Oncology (Williston Park, NY)
Rupesh Kotecha, Jacob A Miller, Vyshak A Venur, Alireza M Mohammadi, Samuel T Chao, John H Suh, Gene H Barnett, Erin S Murphy, Pauline Funchain, Jennifer S Yu, Michael A Vogelbaum, Lilyana Angelov, Manmeet S Ahluwalia
OBJECTIVE The goal of this study was to investigate the impact of stereotactic radiosurgery (SRS), BRAF status, and targeted and immune-based therapies on the recurrence patterns and factors associated with overall survival (OS) among patients with melanoma brain metastasis (MBM). METHODS A total of 366 patients were treated for 1336 MBMs; a lesion-based analysis was performed on 793 SRS lesions. The BRAF status was available for 78 patients: 35 had BRAF mut and 43 had BRAF wild-type ( BRAF-WT) lesions. The Kaplan-Meier method evaluated unadjusted OS; cumulative incidence analysis determined the incidences of local failure (LF), distant failure, and radiation necrosis (RN), with death as a competing risk...
July 2018: Journal of Neurosurgery
Hannah Wang, Pauline Funchain, Gurkan Bebek, Jessica Altemus, Huan Zhang, Farshad Niazi, Charissa Peterson, Walter T Lee, Brian B Burkey, Charis Eng
BACKGROUND: While the role of the gut microbiome in inflammation and colorectal cancers has received much recent attention, there are few data to support an association between the oral microbiome and head and neck squamous cell carcinomas. Prior investigations have been limited to comparisons of microbiota obtained from surface swabs of the oral cavity. This study aims to identify microbiomic differences in paired tumor and non-tumor tissue samples in a large group of 121 patients with head and neck squamous cell carcinomas and correlate these differences with clinical-pathologic features...
February 7, 2017: Genome Medicine
Pranab K Mukherjee, Pauline Funchain, Mauricio Retuerto, Richard J Jurevic, Nicole Fowler, Brian Burkey, Charis Eng, Mahmoud A Ghannoum
BACKGROUND: Metabolomics represents a promising approach for discovering novel targets and biomarkers in head and neck squamous cell carcinoma (HNSCC). Here we used metabolomics to identify oral metabolites associated with HNSCC. METHODS: Tumor and adjacent normal tissue from surgical resections and presurgical oral washes as well as oral washes were collected from healthy participants. Metabolites extractions of these samples were analyzed by liquid chromatography-mass spectroscopy (LC/MS), LC/MS/MS and gas chromatography-MS (GC/MS)...
June 2017: BBA Clinical
Camille Ragin, Jeffrey C Liu, Gieira Jones, Olubunmi Shoyele, Bukola Sowunmi, Rachel Kennett, Harry J M Groen, Denise Gibbs, Elizabeth Blackman, Michael Esan, Margaret S Brandwein, Karthik Devarajan, Francesco Bussu, Rebecca Chernock, Chih-Yen Chien, Marc A Cohen, El-Mofty Samir, Suzuki Mikio, Gypsyamber D'Souza, Pauline Funchain, Charis Eng, Susanne M Gollin, Angela Hong, Yuh-S Jung, Maximilian Krüger, James Lewis, Patrizia Morbini, Santo Landolfo, Massimo Rittà, Jos Straetmans, Krisztina Szarka, Ruth Tachezy, Francis P Worden, Deborah Nelson, Samuel Gathere, Emanuela Taioli
The landscape of HPV infection in racial/ethnic subgroups of head and neck cancer (HNC) patients has not been evaluated carefully. In this study, a meta-analysis examined the prevalence of HPV in HNC patients of African ancestry. Additionally, a pooled analysis of subject-level data was also performed to investigate HPV prevalence and patterns of p16 (CDNK2A) expression amongst different racial groups. Eighteen publications (N = 798 Black HNC patients) were examined in the meta-analysis, and the pooled analysis included 29 datasets comprised of 3,129 HNC patients of diverse racial/ethnic background...
December 26, 2016: Carcinogenesis
Brandie Heald, Jessica Marquard, Pauline Funchain
Hereditary cancer syndromes generally account for 5%-10% of malignancies. While these syndromes are rare, affected patients carry significantly elevated risks of developing cancer, as do their at-risk relatives. Identification of these patients is critical to ensure timely and appropriate genetic testing relevant to cancer patients and their relatives. Several guidelines and tools are available to assist clinicians. Patients suspected to have hereditary cancer syndromes should be offered genetic testing in the setting of genetic counseling by a qualified genetics professional...
October 2016: Seminars in Oncology
Sanghee Hong, Pauline Funchain, Abdo Haddad, Joseph Crowe, Nancy Dalpiaz, Jame Abraham
No abstract text is available yet for this article.
March 2016: Journal of Oncology Practice
Davendra P S Sohal, Brian I Rini, Alok A Khorana, Robert Dreicer, Jame Abraham, Gary W Procop, Yogen Saunthararajah, Nathan A Pennell, James P Stevenson, Robert Pelley, Bassam Estfan, Dale Shepard, Pauline Funchain, Paul Elson, David J Adelstein, Brian J Bolwell
Systematic studies evaluating clinical benefit of tumor genomic profiling are lacking. We conducted a prospective study in 250 patients with select solid tumors at the Cleveland Clinic. Eligibility required histopathologic diagnosis, age of 18 years or older, Eastern Cooperative Oncology Group performance status 0-2, and written informed consent. Tumors were sequenced using FoundationOne (Cambridge, MA). Results were reviewed at the Cleveland Clinic Genomics Tumor Board. Outcomes included feasibility and clinical impact...
November 9, 2015: Journal of the National Cancer Institute
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"